TRIAL DETAIL

Phase 1 Study of LOP628 in Adult Patients With cKit-positive Solid Tumors and Acute Myeloid Leukemia

Drug:
Trial Name:
Phase 1 Study of LOP628 in Adult Patients With cKit-positive Solid Tumors and Acute Myeloid Leukemia
NCT#:
Conditions:
Gastrointestinal Stromal Tumor
Status:
Terminated
Phase:
1
Start Date 12/01/2014
Age of Trial (yrs) 10
Treatment Phase:
Gleevec-resistant
Drug Category:
c-KIT Antibody
Strategy:
Block KIT
Trial Type:
Specifically GIST plus other cancers
Other Protocol IDs:
CLOP628X2101
Sponsor:
Novartis
Patient Contact:
Novartis Pharmaceuticals 1-888-669-6682 +41613241111
Contact email:
Contact Phone:
Randomized:
IV or Oral:
Intravenous
Trial Notes:
For patients with solid tumors:

documented cKit-positive neoplasms
Patient must have progressive disease as defined by any of the following:
SCLC: patient has progressed after at least 1 prior therapy
GIST : patient has relapsed or has refractory disease, and no further approved effective therapeutic option exists
Patients with other cKit-positive solid tumors: patient has progressed after at least one prior line of therapy and no further approved effective therapeutic option exists
Patient has measurable disease as per RECIST v1.1 criteria

Trial Links

Trial Results
 

Drug Information
Preclinical Antitumor Activity of a Novel Anti-c-KIT Antibody-Drug Conjugate against Mutant and Wild-type c-KIT-Positive Solid Tumors
 

Trial Sites

Name
Address
City
State
Zip
Country
Grattan Street
Parkville
Victoria
3050
Australia
450 Brookline Ave
Boston
MA
02215-5450
USA
Leiden
2333
Netherlands